Atea Pharmaceuticals, Inc.
corporate_fare Company Profile
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for AVIR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for AVIR spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Atea 10-Q: $110.5M Nine-Month Loss, $191.2M Cash, and a New CAO Resignation
- Atea Posts Q3 2026 Results; $200M Hercules Facility Extends Cash Runway to Mid-2028
- Atea Signs $200M Hercules Term Loan, Draws $65M at Close
- Atea's C-BEYOND Hits Non-Inferiority: 93.9% SVR vs Epclusa, $2.5B HCV Market in Sight
- Atea's Hepatitis C Drug Hits Phase 3 Goal, Matching Standard of Care
Financial Snapshot
Short Interest & Short Volume
9.55 days to coverFINRA reported short interest of 3,008,126 shares in AVIR as of the October 30, 2026 settlement, a 2.0% decrease from the prior period — about 9.6 days to cover at its recent average daily volume. On November 20, 2026, 39.1% of AVIR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.